Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04781088
Title Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Floor Backes

endometrial cancer

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer


Lenvatinib + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.